Research peptide head to head
Ipamorelin vs Sermorelin
Both peptides appear in growth-hormone preclinical literature, but they act at different receptors. Sermorelin is a GHRH analogue acting on the hypothalamic GHRH receptor pathway. Ipamorelin is a GHRP (growth hormone releasing peptide) acting at the ghrelin receptor. The two are pharmacologically complementary in research models, often combined in preclinical literature. Neither has a UK marketing authorisation as a medicine.
| Ipamorelin | Sermorelin | |
|---|---|---|
| Class | GHRP (ghrelin receptor agonist) | GHRH analogue |
| Amino acids | 5 | 29 |
| Mechanism | Acts at GHSR-1a (ghrelin receptor) | Mimics endogenous GHRH at pituitary |
| Developer | Novo Nordisk | Salk Institute / Serono |
| Most-studied research direction | Postoperative ileus (discontinued phase II) | Childhood growth-hormone deficiency (Geref, discontinued) |
| Half-life | Approx 2 hours | 10 to 20 minutes |
| UK regulatory status | No marketing authorisation; research use only | No marketing authorisation; research use only |
| Pairing in research literature | Often combined with GHRH analogues | Often combined with GHRPs |
| Typical retail price (per equivalent vial) | Mid-range | Higher (longer synthesis) |
Cross-reference: Ipamorelin encyclopedia · Sermorelin encyclopedia.
Ready to buy
Shop UK peptides, collagen and GLP-1 routes
Compare UK retailers, clinics and pharmacies across every PeptideClear category.